Matthew A Warner1, Arun Chandran2, Ryan D Frank3, Daryl J Kor1. 1. From the Department of Anesthesiology and Perioperative Medicine, Division of Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. 2. Internal Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts. 3. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Thrombocytopenia is frequently encountered in critically ill patients, often resulting in prophylactic transfusion of platelets for the prevention of bleeding complications. However, the efficacy of this practice remains unclear. The objective of this study was to determine the relationship between prophylactic platelet transfusion and bleeding complications in critically ill patients. METHODS: This is a retrospective cohort study of adults admitted to surgical, medical, or combined medical-surgical intensive care units (ICUs) at a single academic institution between January 1, 2009, and December 31, 2013. Inclusion criteria included age ≥18 years and a platelet count measured during ICU admission. Propensity-matched analyses were used to evaluate associations between prophylactic platelet transfusions and the outcomes of interest with a primary outcome of red blood cell transfusion in the ensuing 24 hours and secondary outcomes of ICU and hospital-free days and changes in sequential organ failure assessment scores. RESULTS: A total of 40,693 patients were included in the investigation with 3227 (7.9%) receiving a platelet transfusion and 1065 (33.0%) for which platelet transfusion was prophylactic in nature. In propensity-matched analyses, 994 patients with prophylactic platelet transfusion were matched to those without a transfusion. Patients receiving prophylactic platelets had significantly higher red blood cell transfusion rates (odds ratio 7.5 [5.9-9.5]; P < .001), fewer ICU-free days (mean [standard deviation] 20.8 [9.1] vs 22.7 [8.3] days; P = .004), fewer hospital-free days (13.0 [9.7] vs 15.8 [9.4] days; P < .001), and less improvement in sequential organ failure assessment scores (mean decrease of 0.2 [3.6] vs 1.8 [3.3]; P < .001) in the subsequent 24 hours. These findings appeared robust, persisting in multiple predefined sensitivity analyses. CONCLUSIONS: Prophylactic administration of platelets in the critically ill was not associated with improved clinical outcomes, though residual confounding may exist. Further investigation of platelet transfusion strategies in this population is warranted.
BACKGROUND:Thrombocytopenia is frequently encountered in critically illpatients, often resulting in prophylactic transfusion of platelets for the prevention of bleeding complications. However, the efficacy of this practice remains unclear. The objective of this study was to determine the relationship between prophylactic platelet transfusion and bleeding complications in critically illpatients. METHODS: This is a retrospective cohort study of adults admitted to surgical, medical, or combined medical-surgical intensive care units (ICUs) at a single academic institution between January 1, 2009, and December 31, 2013. Inclusion criteria included age ≥18 years and a platelet count measured during ICU admission. Propensity-matched analyses were used to evaluate associations between prophylactic platelet transfusions and the outcomes of interest with a primary outcome of red blood cell transfusion in the ensuing 24 hours and secondary outcomes of ICU and hospital-free days and changes in sequential organ failure assessment scores. RESULTS: A total of 40,693 patients were included in the investigation with 3227 (7.9%) receiving a platelet transfusion and 1065 (33.0%) for which platelet transfusion was prophylactic in nature. In propensity-matched analyses, 994 patients with prophylactic platelet transfusion were matched to those without a transfusion. Patients receiving prophylactic platelets had significantly higher red blood cell transfusion rates (odds ratio 7.5 [5.9-9.5]; P < .001), fewer ICU-free days (mean [standard deviation] 20.8 [9.1] vs 22.7 [8.3] days; P = .004), fewer hospital-free days (13.0 [9.7] vs 15.8 [9.4] days; P < .001), and less improvement in sequential organ failure assessment scores (mean decrease of 0.2 [3.6] vs 1.8 [3.3]; P < .001) in the subsequent 24 hours. These findings appeared robust, persisting in multiple predefined sensitivity analyses. CONCLUSIONS: Prophylactic administration of platelets in the critically ill was not associated with improved clinical outcomes, though residual confounding may exist. Further investigation of platelet transfusion strategies in this population is warranted.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Richard Strauss; Markus Wehler; Katrin Mehler; Daniela Kreutzer; Corinna Koebnick; Eckhart G Hahn Journal: Crit Care Med Date: 2002-08 Impact factor: 7.598
Authors: Richard M Kaufman; Benjamin Djulbegovic; Terry Gernsheimer; Steven Kleinman; Alan T Tinmouth; Kelley E Capocelli; Mark D Cipolle; Claudia S Cohn; Mark K Fung; Brenda J Grossman; Paul D Mintz; Barbara A O'Malley; Deborah A Sesok-Pizzini; Aryeh Shander; Gary E Stack; Kathryn E Webert; Robert Weinstein; Babu G Welch; Glenn J Whitman; Edward C Wong; Aaron A R Tobian Journal: Ann Intern Med Date: 2015-02-03 Impact factor: 25.391
Authors: Luke J Matzek; Andrew C Hanson; Phillip J Schulte; Kimberly D Evans; Daryl J Kor; Matthew A Warner Journal: Anesth Analg Date: 2021-03-01 Impact factor: 6.627
Authors: Alexander P Vlaar; Simon Oczkowski; Sanne de Bruin; Marije Wijnberge; Massimo Antonelli; Cecile Aubron; Philippe Aries; Jacques Duranteau; Nicole P Juffermans; Jens Meier; Gavin J Murphy; Riccardo Abbasciano; Marcella Muller; Akshay Shah; Anders Perner; Sofie Rygaard; Timothy S Walsh; Gordon Guyatt; J C Dionne; Maurizio Cecconi Journal: Intensive Care Med Date: 2020-01-07 Impact factor: 17.440